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Abstract
Background: Hepatitis E, caused by the hepatitis E virus (HEV), is endemic to developing
countries where it manifests as waterborne outbreaks and sporadic cases. Though generally self-
limited with a low mortality rate, some cases progress to fulminant hepatic failure (FHF) with high
mortality. With no identified predictive or diagnostic markers, the events leading to disease
exacerbation are not known. Our aim is to use proteomic tools to identify biomarkers of acute
and fulminant hepatitis E.
Results: We analyzed proteins in the plasma and urine of hepatitis E patients and healthy controls
by two-dimensional Differential Imaging Gel Electrophoresis (DIGE) and mass spectrometry, and
identified over 30 proteins to be differentially expressed during acute hepatitis E. The levels of one
plasma protein, transthyretin, and one urine protein, alpha-1-microglobulin (α1m), were then
quantitated by enzyme immunoassay (EIA) in clinical samples from a larger group of patients and
controls. The results showed decreased plasma transthyretin levels (p < 0.005) and increased urine
α1m levels (p < 0.001) in acute hepatitis E patients, compared to healthy controls. Preliminary
results also showed lower urine zinc alpha glycoprotein levels in fulminant hepatitis E compared to
acute disease; this remains to be confirmed with more fulminant cases.
Conclusion: Our results demonstrate the utility of characterizing plasma and urine proteomes for
signatures of the host response to HEV infection. We predict that plasma transthyretin and urine
α1m could be reliable biomarkers of acute hepatitis E. Besides the utility of this approach to
biomarker discovery, proteome-level changes in human biofluids would also guide towards a better
understanding of host-virus interaction and disease.
Background
Hepatitis E is a significant public health problem in
resource-limited regions of the world. The disease is
caused by the hepatitis E virus (HEV), and appears as spo-
radic cases as well as large localized outbreaks of acute
hepatitis [1]. The HEV is a non-enveloped virus with a
~7.2 kb positive-strand RNA genome and is classified in
the family Hepeviridae [2]. Due to a possible zoonotic
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and occasional sporadic disease [7] have also been
observed in developed countries.
The disease is mild to moderate in severity with a 0.5 to
4% mortality rate [1]. However, it presents with increased
severity and mortality approaching 15-25% in pregnant
women, especially those infected in the third trimester of
pregnancy [8]. While the disease is largely self-limited, a
small fraction of sporadic cases progress to fulminant
hepatic failure (FHF) with high mortality; this is also
observed in infected pregnant women [1]. The obstetric
and fetal outcomes are reported to be worse for pregnant
women infected with HEV compared to other hepatitis
viruses [9]. The events leading to FHF are not known and
no predictive or diagnostic markers are available. Diag-
nostic tests routinely employed for HEV infection include
evaluation of circulating IgM antibodies to viral compo-
nents, occasional evaluation of viral RNA by reverse tran-
scription polymerase chain reaction (RT-PCR) and the
biochemical assessment of liver function [1]. None of
these tests shed any light on disease prognosis. The avail-
ability of predictive biomarkers of disease progression
would aid in identifying those sporadic cases that are
more likely to develop severe disease, and would thus aid
in patient care and management.
The outcome of an infection depends upon multiple fac-
tors, both pathogen-related and host-related. Changes in
the host proteome following infection have been docu-
mented for a number of human pathogens [10]. Genomic
and proteomic biomarkers are proving to be particularly
useful in understanding disease progression, staging and
response to therapy in chronic diseases and cancers
[11,12]. Since disease progression also depends upon the
host response to infection, examination of differential
protein expression profiles from diseased versus healthy
individuals is a good starting point to search for potential
markers of disease progression.
Body fluids such as plasma and urine being in close con-
tact with cells and tissues are good representatives of the
host physiology. Proteomic methods such as two-dimen-
sional gel electrophoresis (2DGE) and differential imag-
ing gel electrophoresis (DIGE) followed by the mass
spectrometric identification of proteins are being
employed to compare signatures in body fluids from
patients and controls [13,14]. We have applied these pro-
teomic methods to compare plasma and urine from hep-
atitis E patients and healthy controls. Our results show
changes in multiple proteins from both analytes, two of
which were also validated in a larger sample set.
Methods
Subjects
Specimens were obtained from patients with jaundice at
the Gastroenterology Outpatient Clinic or inpatients at
the Army Base Hospital in New Delhi, India. Specimens
were also obtained from healthy volunteers. Blood (5-6
ml) was collected in EDTA-coated vacutainers (Becton
Dickinson), centrifuged at 800 × g for 5 min at 4°C. The
plasma was collected and stored in aliquots at -70°C. It
was tested for various viral hepatitis markers by enzyme
immunoassays (EIA) as follows: HBsAg (Hepalisa, J Mitra
and Co. Pvt. Ltd., New Delhi, India), anti-HCV (Hep-
Chex-C, XCyton Diagnostic Pvt. Ltd., Bangalore, India),
and IgM anti-HEV (HEV IgM ELISA, MP Biomedicals Asia
Pacific Pvt. Ltd., Singapore). First morning mid-stream
urine (~150 ml) was collected in an autoclaved bottle
containing one protease inhibitor cocktail tablet (Roche,
Germany), and stored at -70°C.
Plasma fractionation and dye labelling
The plasma samples were first depleted of the six most
abundant proteins using a MARS spun column (Agilent
Technologies, USA) according to the manufacturer's pro-
tocol. Briefly, 15 μl of plasma was diluted in 185 μl of
Buffer A, passed through a spin pre-column and then
loaded onto the MARS column. The depleted fraction was
collected as flow through and the bound proteins were
eluted with Buffer B as recommended. The plasma
depleted of 85-90% of albumin, immunoglobulin G
(IgG), IgA, haptoglobin, anti-trypsin and transferrin was
then cleaned up using the Clean-Up kit (GE Healthcare,
UK) according to the manufacturer's protocol, and the
protein content was estimated using the Bradford Reagent
(Bio-Rad Laboratories). Pools of plasma specimens
obtained from four patients (HEV pool) and four healthy
volunteers (NOR pool) were prepared by mixing individ-
ual protein-depleted plasma in volumes that contained
equal amounts of total protein. The protein pools were
separately resuspended in DIGE buffer (8 M Urea, 4%
CHAPS, 10 mM Tris-Cl, pH 8.5) to give a final protein
concentration of 0.75 mg/ml. Cyanine dyes (Cy2, Cy3 or
Cy5; GE Healthcare, UK) were reconstituted in anhydrous
dimethylformamide and added to labelling reactions at a
ratio of 400 pmoles of Cy Dye per 50 μg of protein. The
reactions were kept for 30 min on ice in the dark and were
terminated by the addition of 1 μl of 10 mM lysine for 10
min. The HEV and NOR pools were labelled with Cy5 and
Cy3, respectively. An equal mixture of the two pools was
also labelled with Cy2 and used as an internal control rep-
resenting the total proteins. The labelled samples were
either immediately fractionated further or were stored at -
70°C.Page 2 of 14
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Equal volumes of the samples labelled with Cy2, Cy3 and
Cy5 dyes were mixed together and dialyzed against MLAC
equilibration buffer (EB; 20 mM Tris-Cl, pH 7.4, 150 mM
NaCl, 1 mM CaCl2, 1 mM MnSO4) overnight at 4°C with
three changes of buffer. The MLAC column was prepared
by mixing 700 μl packed bed volume each of Wheat Germ
Agglutinin (WGA) agarose, Concavalin A (Con A) agarose
and Jacalin agarose (Vector Laboratries, Inc., USA), and
equilibrated with EB. The dialyzed proteins were applied
to the column and allowed to bind. The flow through was
recycled through the column once and then collected as
the non-glycosylated fraction. The glycosylated proteins
were then eluted using a displacer buffer (20 mM Tris-Cl,
pH 7.4, 500 mM NaCl, 170 mM methyl α-D mannopyra-
noside, 270 mM galactose, 170 mM N-acetylglu-
cosamine). The glycosylated and non-glycosylated plasma
protein fractions thus obtained were either fractionated
further using mixed cation-anion exchange chromatogra-
phy (CAX) or were resolved using two-dimensional gel
electrophoresis (2DGE).
Mixed cation-anion exchange chromatography (CAX)
A mixed cation-anion exchange chromatography column
was prepared with an equal mixture of S-Sepharose and
Q-Sepharose (GE Healthcare, UK), and was equilibrated
with 20 mM Tris-HCl pH 7.5. The glycosylated and non-
glycosylated fractions were first dialysed against the CAX
equilibration buffer overnight at 4°C with three changes
and were separately applied to the column. After binding,
the column was washed with two volumes of 20 mM Tris-
HCl pH 7.5, and the bound proteins eluted with two vol-
umes of a gradient of 100-600 mM NaCl in 20 mM Tris-
HCl pH 7.5 (in steps of 100 mM NaCl). The fractions thus
obtained were resolved by SDS-12%PAGE, the gels
scanned on a Typhoon Imager (GE Healthcare, UK) and
then silver stained to pick the bands for mass spectromet-
ric analysis.
Urine fractionation and dye labelling
Urine samples (50 ml) were centrifuged at 3,000 × g for 5
min at 4°C and the supernatant filtered through a What-
mann P3 paper. The filtrate was then dialyzed using a 3.5
kDa cut-off dialysis membrane (Pierce, USA) against Mil-
liQ water overnight at 4°C with three changes. The dia-
lysed sample was precipitated with 66% chilled acetone
for 20 min on ice, followed by centrifugation at 12,000 ×
g for 20 min. The pellets were resuspended in a buffer con-
taining 4 M Urea and 2% CHAPS, and the protein concen-
tration estimated using the Bradford reagent (Bio-Rad
Laboratories, USA). Labelling of the protein samples with
Cy dyes was carried out as described for plasma proteins.
Two-dimensional gel electrophoresis (2DGE)
The fractionated plasma proteins were precipitated with
acetone at -20°C for 2 hr and then resuspended in rehy-
dration buffer (8 M Urea, 2% CHAPS, 0.2% Bromophenol
Blue, 20 mM DTT, 0.78% Pharmalyte). An IPGphor IEF
unit and precast 13 cm, pH 3-10 NL IPG strips (GE
Healthcare, UK) were used for the first dimension separa-
tion. The strips were rehydrated for 12 hr in rehydration
buffer, 100 μg protein was loaded actively and resolved
for a total focusing time of 32 KVhr. Each strip was then
equilibrated with 5 ml equilibration buffer A (30% Glyc-
erol, 6 M Urea, 50 mM Tris-HCl, pH 8.8, 2% SDS, 0.2%
Bromophenol blue, 10 mg/ml dithiothreitol) on a rocker
for 30 min at room temperature, followed by buffer B
(30% Glycerol, 6 M Urea, 50 mM Tris-HCl, pH 8.8, 2%
SDS, 0.2% Bromophenol blue, 25 mg/ml Iodoacetamide)
for another 30 min at room temperature with rocking. The
proteins were resolved in the second dimension at room
temperature on SDS-10% polyacrylamide gels at 10 mA
per gel for 30 min, followed by 20 mA per gel.
For the urine samples, 100 μg of labelled proteins were
passively loaded during rehydration on 13 cm, pH 3.0-5.6
NL IPG strips for 12 hr at room temperature. The samples
were focussed in the first dimension for 31 KVhr followed
by strip treatment and second dimension as described
above for plasma proteins.
The gels were scanned with an Ettan DIGE Scanner (GE
Healthcare, UK) and analysed using the DeCyder 2D v6.5
software (GE Healthcare, UK). The intensity of each spot
was normalized against the Cy2 labelled control. Only the
spots that were significantly changed (= 1.5 fold increase
or decrease) in the patients as compared to controls were
selected for mass spectrometric analysis after silver stain-
ing of the gels.
Mass spectrometry and protein identification
The gel plug was washed once with water, twice for 10 min
each with vortexing in destaining solution (15 mM Potas-
sium Ferricyanide, 50 mM Sodium Thiosulphate), twice
in water for 15 min each, and then for 5 min with 100 μl
of a solution containing 10 mM Ammonium Bicarbonate
and 50% Acetonitrile (ACN). The proteins were reduced
with 150 μl of 10 mM Dithiothreitol, 100 mM Ammo-
nium Bicarbonate, 5% ACN for 1 hr at 55°C, followed by
dehydration of the plug in 100 μl of 100% ACN for 20
min, and the proteins were alkylated with 100 μl of 50
mM Iodoacetamide in 100 mM Ammonium Bicarbonate
for 30 min at room temperature, in the dark. The plugs
were then washed with 100 μl of 100 mM Ammonium
Bicarbonate for 10 min, followed by 100 μl of 100% ACN
for 20 min. The liquid was removed and the plugs dried
in a SpeedVac for 15 min. The proteins in gel plugs were
then digested at 37°C with 150-200 ng trypsin in 50 mMPage 3 of 14
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were collected in the supernatant, the gel plugs treated
once with 100 μl of 20 mM Ammonium Bicarbonate,
twice with 100 μl of 1% Trifluoroacetic acid (TFA) in 50%
ACN for 20 min, and once with 100 μl of 100% ACN for
20 min. All the supernatants were pooled together and
concentrated in a SpeedVac to 10 μl. From this, 1 μl of the
sample was mixed with 1 μl of α-Cyano-4-hydroxycin-
namic acid (5 mg/ml in 50% acetonitrile, 0.1% TFA,
Bruker Daltonics) matrix, and analyzed on the Bruker
Ultraflex MALDI-TOF-TOF mass spectrometer with Flex
Control v2.2, and processed using Flex analysis v2.2 soft-
ware. The standard peptide mixture (a mixture of nine
peptides from the m/z range of 757-3147) was used for
external mass calibration, while self-degraded fragments
of trypsin were used for internal calibration. Spectra were
acquired for the mass-to-charge (m/z) range of 800-4000.
All samples were analyzed in reflectron mode at laser
power of 20-25%. Each spectrum was the sum of 500 laser
shots with laser frequency of 50 Hz. The peak lists for MS
were generated using Flex control version 2.2 and Flex
analysis version 2.2 (Bruker Daltonics) using a proprietary
"Top hat" base-line tool along with "SNAP" peak detec-
tion algorithm, which was set to a signal-to-noise ratio of
6, maximal number of peaks as 100 and quality factor
threshold of 50. The MS/MS was smoothed and base line
subtracted and the peptide mass list was searched against
the MSDB database using the MASCOT search engine
(BioTools v 2.2 software). MS/MS spectra were also proc-
essed using Flexanalysis v 2.2 software and searched using
MASCOT. The mass spectrum data were submitted to an
online database for protein identification (MASCOT ver-
sion 2.1, http://www.matrixscience.com/).
The search parameters were set as follows: Database -
MASCOT; enzyme - trypsin; taxonomy - Homo sapiens;
global modification of carbamidomethyl on cysteine;
with variable modification of oxidation on methionine;
no restrictions on protein mass; allowed up to 1 missed
cleavage. The peptide tolerance was set at 100 ppm and
MS/MS tolerance at ± 0.8-1.0 Da. For PMF, only those pro-
teins with score >60 (p < 0.05) were accepted as identified,
while for MS/MS individual ion cut off score was set as 39
or 41 (p < 0.05). The false discovery rate (FDR) was calcu-
lated using decoy database (MASCOT) and was 0.0% for
most of the proteins (see Additional file 1). Xcorr was cal-
culated for those proteins that were run on Thermo LCQ
Deca nano LCMS and was searched in Sequest database.
The Xcorr cut off was kept at 10.0 and the same data in
.mgf format was also searched in MASCOT database and
FDR calculated in decoy database. As to those peptides
matched to multiple members of a protein family, the one
with the highest score was reported. Most of the proteins
identified were found to have more than two peptide
matches in database however for few proteins with single
peptide match, the sequence provided by the database
was manually validated and those with reasonably good
'b and y' ion matches were considered (see Additional file
2, Additional file 3, Additional file 4 and Additional file
5). During protein identity validation due importance was
also given to the theoretical molecular weight and isoelec-
tric points of the proteins. The proteins with theoretical
mass and isoelectric points approximately equal to the
experimentally obtained values were accepted as success-
fully identified.
Enzyme immunoassays (EIA)
For the quantitation of transthyretin and alpha-1-
microglobulin (α1m) in body fluids, commercial EIA kits
(Immunology Consultants Laboratory, Inc., USA) were
used. The levels of transthyretin were assayed in plasma as
per the manufacturer's protocol. To estimate α1m levels,
urine was centrifuged at 3,000 × g for 5 min at 4°C. From
this, 10 μL of the supernatant was diluted 100-fold with
the diluent provided in the kit, and the assay carried out
according to the manufacturer's protocols. The quantity of
a specific protein in the test sample was interpolated from
standard curves and corrected for sample dilution.
Depending upon the viral markers, the samples were
divided into five groups: Group 1, positive for HEV and
negative for other viral hepatitis markers [HEV+/Other-]
(n = 20); Group 2, positive for HEV and HBV [HEV+/
HBV+] (n = 5); Group 3, negative for HEV but positive for
HBV [HEV-/HBV+] (n = 5); Group 4, clinical diagnosis of
viral hepatitis but negative for all viral markers [All-] (n =
4); Group 5, healthy controls (n = 20).
Statistical analysis
Statistical significance of the data was evaluated with par-
ametric as well as non-parametric methods. The former
included the Student's t-test and the latter included the
Mann-Whitney U test. These packages were part of the
Past software [15]. P values of < 0.05 were considered sig-
nificant. Receiver operating characteristic or ROC curve
was generated using SPSS software (version 15.0). Area
under the curve (AUC) was calculated and AUC values
above 0.75 were considered.
Results
Plasma fractionation and analysis
Since the dynamic range of human plasma is high, we
tried different proteomic workflows using pools of patient
and control plasma labelled with cyanine dyes (Fig. 1). In
workflow A, we separated labelled proteins into glyco-
sylated and non-glycosylated fractions through multi-lec-
tin affinity chromatography (MLAC) followed by a
charge-based separation by mixed cation-anion exchange
chromatography (CAX). These fractions were then ana-
lyzed by SDS-PAGE. In workflow B, the MLAC-derivedPage 4 of 14
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analyzed by two-dimensional gel electrophoresis (2DGE).
The main problem encountered with workflow A was the
dilution of proteins at the end of the workflow, making it
difficult to detect many proteins following SDS-PAGE and
DIGE scans. From the non-glycosylated CAX fractions, we
observed three proteins (NG-1, NG-3 and NG-4) to be
downregulated in hepatitis E patients, and one protein
(NG-2) that remained unchanged between patients and
healthy controls (Fig. 2A). These were identified by mass
spectrometry to be apolipoprotein A1 (NG-1), vitamin D
binding protein (NG-2), and transthyretin or prealbumin
(NG-3 and NG-4) (Table 1).
For workflow B, representative 2DGE patterns for the glyc-
oprotein (Fig. 2B(1)) and non-glycoprotein fractions (Fig.
2B(2)) are shown. Various spots were marked using the
DeCyder software and image analysis was carried out
based on spot volume and intensity. Two independent
sets of experiments with different patient and control
pools were analysed. Representative gel images are shown
for one set. In the glycoprotein fraction, of the 219 spots
analyzed, 67 (30.6%) proteins were downregulated and
22 (10%) were upregulated in hepatitis E patients, while
130 (59.4%) remained unchanged. In the non-glycopro-
tein fraction, of the 102 spots analyzed, 34 (33.3%) pro-
teins were downregulated and 33 (32.3%) were
upregulated in hepatitis E patients, while 35 (34.3%)
Workflow for proteomic analysisFigure 1
Workflow for proteomic analysis. Proteins in the plasma or urine of healthy controls and hepatitis E patients were labelled 
with Cy2, Cy3 or Cy5 dyes as described in Methods. The labelled samples were mixed and subjected to different fractionation 
strategies. In workflow A, the labelled samples were first subjected to Multi Lectin Affinity Chromatography (MLAC) to obtain 
fractions enriched in glycoproteins (G fraction) and non-glycoproteins (NG fraction). These fractions were then separately 
fractionated by mixed cation-anion exchange chromatography (CAX). The six fractions obtained by step salt elution were then 
analysed by SDS-PAGE. In workflow B, the labelled samples were subjected to MLAC and the enriched fractions were resolved 
by two-dimensional gel electrophoresis (2DGE). Workflows A and B were followed for plasma samples. Workflow C was fol-
lowed for urine samples for which the labelled samples were directly fractionated by 2DGE. The differentially expressed spots 
were analysed with DeCyder 2D v6.5, the selected spots were cut out and the proteins identified by mass spectrometry.Page 5 of 14
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2B) were excised and the proteins identified by mass spec-
trometry. The identity of these proteins and their average
fold-changes in the plasma of hepatitis E patients versus
controls in the two sets are shown in Table 1.
Urine fractionation and analysis
The protein content and dynamic range in urine is much
lower than plasma. We therefore followed workflow C
(Fig. 1) for analyzing urine samples from hepatitis E
patients and controls. Various sets of samples were ana-
lyzed by 2DGE, DIGE scanning and quantitation using
Analysis of plasma fractionsFigure 2
Analysis of plasma fractions. (A) Workflow A, NG fraction separated by CAX. Lanes: 1, NG fraction; 2, CAX flow-through 
fraction; 3-8, CAX eluates with 100, 200, 300, 400, 500 or 600 mM NaCl. The boxed bands NG-1, NG-2, NG-3 and NG-4 
were identified by mass spectrometry. (B) DIGE images of (1) glycosylated and (2) non-glycosylated protein enriched fractions 
resolved by 2DGE. The proteins in spots P1 to P14 were identified by mass spectrometry and are shown in Table 1.Page 6 of 14
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Table 1: Differentially expressed plasma proteins
Identifier Protein Name Accession Number Glyco/Non-Glyco Fold-change Acute phase reactant
P1 Lipocalin
Plasma retinol binding protein
AAF69622
1RBP
NG/G -1.47(NG)
+1.32(NG)
-7.68(G)
-6.09(G)
No
?(-)
P2 Transthyretin (prealbumin) AAA61181 NG Yes(-)
NG-3 - Transthyretin precursor
- Interleukin 6 signal transducer isoform 1 
precursor
- Sequence 17 from patient EP1229047 
unnamed protein product
- HS422F24 chromosome 6 orf1
AAA61181
CAD48779
CAD48776
CA120537
NG Yes(-)
NG-4 - Transthyretin (prealbumin)
- Annexin A2 (Annexin II) (Lipocortin II) 
(Calpactin I Heavy Chain)
- Possible J56 gene segment (fragment)
VBHU
ANXA2_HUMAN
NG Yes(-)
P3 Fibrinogen chain FGHUB G +1.14
-1.59
Yes(+)
P4 - Alpha-2-HS glycoprotein
- Cystatin C
WOHU
AAF69649
G +1.45
+1.02
Yes(-)
No
P5 HP-Protein Haptoglobin Q6NSB4 AAC27432 G -2.27
-2.85
Yes (+)
P6 Beta-2 glycoprotein 1 1QUBA G -1.36
-2.58
No
P8 Alpha1 acid glycoprotein precursor 2
Alpha1 acid glycoprotein precursor 1
OMHU2
OMHU1
Q61B74
G -2.15
-2.33
Yes (+)
P9 Fibrinogen FGHUB G -0.82
-2.24
Yes (+)
P10 Hemopexin CAA26382 G -2.71
-2.78
Yes (+)
P11 Apolipoprotein A1 CAA00975 NG/G -3.03(G)
-7.90(G)
-1.47(NG)
-1.38(NG)
No
NG-1 Apolipoprotein A1 CAA00975 NG/G
P12 Fibrinogen γ-A chain precursor
Fibrinogen γ-B chain precursor
FGHUG
FGHUGB
NG/G +2.20(NG)
+1.51(NG)
P13 Tau Tubulin Kinase
Hypothetical protein DKFZp686J1375
Q8IWY7
Q7Z3Q0
NG +1.49
+1.43
No
P14 NG +2.43
+2.94
P15 Serum Amyloid P Precursor YLHUP G -2.52 Yes (+)
NG-2 Vitamin D Binding Protein
The differentially expressed plasma proteins from Figure 2 were analysed by DeCyder 2D v6.5 and identified by mass spectrometry. The table 
shows the spot intensity fold-changes in hepatitis E patients compared to healthy controls in two independent plasma pool experiments. The "+" 
and "-" values indicate increased or decreased expression, respectively, in patients compared to controls.
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Analysis of the urine proteomeFigure 3
Analysis of the urine proteome. (A) In Workflow C, pooled urine samples were labelled and resolved by 2DGE. (1) DIGE 
image of proteins from pools of healthy normals and hepatitis E patients labelled with Cy3 and Cy5, respectively. (2) DIGE 
image of proteins from pools of hepatitis E patients and healthy normals labelled with Cy3 and Cy5, respectively. (B) DIGE 
image of urine proteins from acute mild hepatitis patient (H3) labelled with Cy3 and those from a case of fulminant hepatitis E 
(H4) labelled with Cy5. Box 1 shows proteins spots that were downregulated in fulminant hepatitis compared to acute mild 
infection, while Box 2 shows proteins that remained unchanged between the two forms of disease.
Proteome Science 2009, 7:39 http://www.proteomesci.com/content/7/1/39the DeCyder software, as described in Methods. Pools of
6 healthy and 9 hepatitis E patient urine samples were
separately labelled with Cy3 and Cy5, respectively and
analyzed according to workflow C. The DIGE image is
shown in Fig. 3A (1). Of the 1177 spots subjected to
image analysis, 38.3% proteins were upregulated and
22.5% proteins downregulated in acute hepatitis E, while
39.2% remained unchanged. A dye swap experiment was
also carried out with the same pools, except that the hep-
atitis E patient samples were now labelled with Cy3 and
the normal samples with Cy5. The DIGE image for this is
shown in Fig. 3A (2). For 765 spots, image analysis
showed comparable results with 33.5% proteins upregu-
lated and 30.2% proteins downregulated in acute hepati-
tis E, and 36.3% remaining unchanged. There was good
concordance for individual proteins as well; this is pre-
sented in Table 2. Our analyses also showed that samples
collected more than 15 days after the onset of symptoms
appeared similar to healthy control samples (not shown).
In this set, only 6% proteins were upregulated, 2% were
downregulated and 92% remained unchanged. Thirteen
differentially expressed protein spots (U1 to U13) were
picked (Fig. 3A) and identified by mass spectrometry. A
list of these proteins and their fold changes during acute
hepatitis E is shown in Table 2.
We also compared the urine proteins from a patient with
acute mild infection (H3) labelled with Cy3 to those from
a patient with fulminant hepatitis E (H4) labelled with
Cy5 (Fig. 3B). Of the 725 spots detected, 80 (11%) were
upregulated and 101 (14%) were downregulated in fulmi-
nant compared to mild hepatitis E infection, while 544
Table 2: Differentially expressed urine proteins
Identifier Protein Name Accession Number Fold Change Expt 1
(HEV Cy5; CON Cy3)
Fold Change Expt 2 
(HEV Cy3; CON Cy5)
U1 Prostaglandin D2 synthase
21 kDa (Brain)
Q5SQ09 +2.16 -1.43
U2 - Zinc alpha 2 glycoprotein chain A
- Alpha 1 type I collagen, preprotein
1ZAGA
Q8N473_HUM
+4.97 -3.14
U3 Zinc alpha 2 glycoprotein chain A 1ZAGA +6.58 -3.74
U4 Zinc alpha 2 glycoprotein chain A 1ZAGA +6.98 -2.94
U5 KIAA0216 splice variant 1 Q5W9G1_HUM +4.40 -1.85
U6 - Membrane associated guanylate 
kinase 2
- ODF2 protein
AAC05370
Q5BJF6_HUM
+3.33 -1.75
U7 FLJ00133 fragment Q8TERO_HUM +9.08 -1.83
U8 Serum albumin AAA64922 -4.06 +8.67
U9 Serum albumin AAA64922 -2.52 +6.67
U10 N2B-Titin Isoform
RasGAP-activating-like protein 1 
variant
CAD12455 +9.42 -3.81
U11 Alpha-1 microglobulin/inter alpha 
trypsin inhibitor precursor
HCHU +6.01 -3.63
U12 Alpha-1 microglobulin/inter alpha 
trypsin inhibitor precursor
HCHU +7.59 -4.21
U13 Alpha-1 microglobulin/inter alpha 
trypsin inhibitor precursor
HCHU +6.22 -2.81
The differentially expressed urine proteins from Figure 3 were analysed by DeCyder 2D v6.5 and identified by mass spectrometry. The table shows 
the spot intensity fold-changes in hepatitis E patients (HEV) compared to healthy controls (CON). A dye swap experiment is also shown. The "+" 
and "-" values indicate increased or decreased expression, respectively, in patients compared to controls.Page 9 of 14
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(Fig. 3B) correspond to proteins U2, U3 and U4, which
were identified as different isoforms of the Zinc Alpha
Glycoprotein (ZAG), and U6 identified as the membrane-
associated guanylate kinase 2, ODF2 protein (Table 2).
The different isoforms of ZAG increased by 40 to 50-fold
in acute hepatitis E compared to healthy controls, but
decreased by 4 to 6-fold during the fulminant stage of dis-
ease, compared to the acute stage. Similarly, the mem-
brane-associated guanylate kinase 2 and ODF2 protein
increased about 17-fold during acute hepatitis E, but
declined by about 3-fold during fulminant disease. Since
this analysis depends upon a single fulminant hepatitis E
sample, these changes require confirmation with more
fulminant cases.
Validation of proteomic results by EIA
The proteomic analyses used a limited number of samples
from hepatitis E patients and controls. It was therefore
important to independently validate representative mark-
ers in a larger sample set. Further, since only acute hepati-
tis E patients were compared to healthy controls in the
proteomic analyses, it was not clear whether the identified
proteins were differentially expressed in all types of viral
hepatitis or were markers specific to hepatitis E. We
looked at one marker each from plasma and urine, for
which enzyme immunoassays (EIA) were commercially
available. This included plasma transthyretin and urine
α1m. Patient samples were divided into five groups
depending upon their viral hepatitis markers, as described
in Methods.
The plasma transthyretin levels were significantly reduced
in HEV mono-infected and HEV/HBV co-infected patients
compared to healthy controls (Fig. 4A). However, patients
with HBV infection (Group 3) or those with a clinical
diagnosis of viral hepatitis without the serological mark-
ers (Group 4) showed no significant association, possibly
due to the low numbers of samples (Fig. 4A). The urine
α1m levels were significantly higher in HEV mono-
infected and HEV/HBV co-infected patients compared to
healthy controls (Fig. 4B). There were no significant
changes in the urine α1m levels in patients in the other
groups compared to controls. The HEV infected patients
(Group 1) also showed significantly higher levels of urine
α1m when compared to HBV infected patients (Group 3)
(Fig. 4B). Area under the curve (AUC) for alpha 1
microglobulin assay was found to be 0.893 (95% confi-
dence intervals = 0.795-0.990) and that for transthyretin
assay was 0.763 (95% confidence intervals = 0.591-
0.934). These analyses indicate that these two markers in
particular urine α1m may be selective for acute hepatitis E
infection.
Discussion
Proteome analysis is a powerful way to study the patho-
physiology of chronic and infectious human diseases
[10]. Comparisons of the proteomes of tissues and bioflu-
ids from diseased and healthy persons have identified
potential biomarkers to predict disease stages, clinical
outcomes and response to therapy [12]. For example, hap-
toglobin and its glycosylated forms have been identified
as potential biomarkers for non-small cell lung cancer and
hepatocellular carcinoma [16,17], calcitonin for thyroid
cancers [18], and gastrin for gastric and colorectal cancers
[19]. A number of studies have also addressed disease
biomarkers, such as decreased α1m in IgA nephropathy
[20] and hepatocyte growth factor for liver dysregulation
[21]. Reduced transferrin and increased alpha-2-mac-
roglobulin in HBV carriers might suggest active liver dis-
ease [22]. Recently, complement C3a was predicted to be
a candidate marker of chronic hepatitis C and HCV related
hepatocellular carcinoma [23]. Some novel proteins asso-
ciated with HCV-induced fibrosis have also been identi-
fied as inter-alpha trypsin inhibitor heavy chain 4 (ITIH4)
fragments, complement factor H-related protein 1, CD5L,
Apo L1, β2GPI, and thioester-cleaved products of alpha-2-
macroglobulin [24]. So far there are no reports on markers
of hepatitis E disease.
We report here the application of DIGE, a fluorescent pro-
tein labelling and gel electrophoresis platform to repro-
ducibly fractionate and identify differentially expressed
protein patterns in the plasma and urine of hepatitis E
patients. One set of proteins that showed differential
expression was the acute phase proteins (APP), whose
plasma concentrations either increase (positive APP) or
decrease (negative APP) during inflammation [25].
Though the APPs have different functions, they are prima-
rily related to host defence. As liver is the major site for
production of these proteins, any infection or dysfunction
of the liver leads to changes in plasma APP levels. In acute
hepatitis E we found the plasma levels of many positive
APPs like haptoglobin, hemopexin, serum amyloid P pre-
cursor and alpha-1 acid glycoprotein to decrease. The hap-
toglobin-hemopexin system is the major vehicle for heme
transport in the plasma and protects from the loss of
heme-bound iron. It protects from oxidative stress and
increases during an inflammatory response [26,27]. The
plasma levels of alpha-1 acid glycoprotein (or orosomu-
coid) increase in response to systemic tissue injury,
inflammation or infection, and these changes have been
correlated to increases in hepatic synthesis. It functions as
an immunomodulator [28] and its downregulation dur-
ing acute hepatitis E is likely to compromise the innate
immune response. The negative APP alpha 2 HS glycopro-
tein (or fetuin), whose plasma levels increase in acute
hepatitis E patients, is anti-inflammatory [29]. We have
previously shown that the ORF3 protein of HEV downreg-Page 10 of 14
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through the STAT3 transcription factor [30]. Thus, by
actively downregulating the expression of plasma proteins
involved in innate immune responses, HEV attenuates
inflammatory responses and creates a favourable environ-
ment for viral replication and establishment of infection.
Transthyretin or pre-albumin is another negative APP
whose levels are a reliable indicator of acute liver disease
[31]. This was found to be differentially expressed in the
plasma of hepatitis E patients. In patients with HEV infec-
tion, whether with or without HBV co-infection, the
plasma transthyretin levels were significantly lower than
those in healthy controls (Fig. 4A).
Validation of representative biomarkers by EIAFigure 4
Validation of representative biomarkers by EIA. The EIAs were carried out as described in Methods. (A) Plasma levels 
of transthyretin were estimated for various groups of hepatitis patients and controls. The p values shown are based on the 
Mann-Whitney test; the significance remains the same with the Student's t-test. (B) The levels of alpha-1-microglobulin in urine 
were estimated for various groups of hepatitis patients and controls. The p-values shown are based on both parametric (Stu-
dent's t test) and non-parametric (Mann-Whitney U test) tests. All p values shown are relative to Group 5, except in (B) in 
which Groups 1 and 3 were also compared.Page 11 of 14
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patients and healthy controls. Urine is an easily available
non-invasive analyte, which has been used extensively for
the diagnosis and monitoring of both renal and systemic
diseases [32]. Being a filtrate of blood, urine also carries
protein components analogous to plasma, but with a
reduced diversity and dynamic range. The levels of α1m
were significantly higher in the urine of hepatitis E
patients compared to healthy controls and patients with
other forms of acute viral hepatitis. Alpha-1-microglobu-
lin is a 31-kDa glycoprotein, which is involved in defend-
ing tissues against oxidation by heme, kynurenin and
reactive oxygen species [33-35], and also functions as an
immunosuppressor [35,36]. Elevated levels of α1m have
also been associated with renal tubular disorders [37]. In
earlier studies, the ORF3 protein of HEV was shown to
expedite the secretion of α1m from infected hepatocytes
[38].
The levels of prostaglandin D2 synthase (PGD2S) were
also found to increase in the urine of hepatitis E patients.
It is a lipocalin involved in the transport of bile pigments,
retinoids, thyroid hormone, bilirubin and biliverdin, as
also a vasodilator produced by inflammatory cells (mast
cells and macrophages), which suppresses the induction
of inducible nitric oxide (NO) synthase, resulting in
reduced inflammation [39]. Though PGD2S levels in
serum and urine have been investigated as an indicator of
renal dysfunction [40,41], there are no reports linking it
to viral hepatitis. Our proteomic observation of increased
levels of PGD2S in the urine of hepatitis E patients awaits
further validation.
While a majority of HEV infections present as self-limited
acute hepatitis, occasional cases present as FHF. The levels
of zinc alpha glycoprotein (ZAG), membrane associated
guanylate kinase 2 and ODF2 were significantly lower in
the urine of a fulminant hepatitis E patient compared to a
patient with mild hepatitis due to HEV. Interestingly,
when compared to healthy persons, the levels of these
proteins are still higher in hepatitis E patients, but as the
disease takes a more severe fulminant form, they are par-
tially cleared from the urine. Though the exact role of ZAG
with respect to viral disease has not been shown, it plays
a role in lipolysis in adipocytes and is involved in the reg-
ulation of body weight [42-44], besides being a soluble
non-conventional major histocompatibility complex
class I molecule [45]. Whether ZAG, membrane associated
guanylate kinase 2 and ODF2 turn out to be potential
markers of fulminant hepatitis E, will await confirmation
from the analysis of more fulminant cases.
We present here the first study to employ proteomic anal-
ysis tools to look for potential biomarkers of hepatitis E
disease. Our results show both plasma and urine to be
analytes that are readily amenable to a differential protein
labelling method such as DIGE followed by fractionation
and mass spectrometric analysis. In a limited study we
also show validation of two potential biomarkers by EIA.
We have also identified a number of host proteins that are
differentially expressed during HEV infection, which
would help better understand the biology of host-patho-
gen interaction.
Conclusion
This study demonstrated that plasma and urine pro-
teomes of hepatitis E patients were amenable to differen-
tial labelling and proteomic analysis methods to discover
signatures of the host response to viral infection. Besides
identifying a number of differentially expressed proteins
in the plasma and urine of hepatitis E patients, this study
also showed that plasma transthyretin and urine α1m
could be reliable biomarkers of acute hepatitis E. Initial
results have also indicated urine proteome differences in
patients with mild and fulminant hepatitis E. Besides the
utility of this approach to biomarker discovery, proteome-
level changes in the biofluids of infected persons would
also guide towards a better understanding of host-virus
interaction and hepatitis E pathogenesis.
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